CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMI2 AMR Accelerator focuses on combating antimicrobial resistance by developing new treatments for infections caused by multidrug-resistant bacteria. The COMBINE project will enhance communication and data sharing among AMR projects, while establishing a supportive infrastructure for research.
The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health.
The IMI2 AMR Accelerator will develop new agents to treat and prevent infections caused by MDR and XDR bacteria, including Mycobacterium tuberculosis and non-tuberculous mycobacteria.
The COMBINE proposal addresses Pillar A, the Capability Building Network (CBN) of the AMR Accelerator programme.
The COMBINE consortium will form a Coordination and Support Office (CSO)…
UPPSALA UNIVERSITET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, BERLIN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Langen
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Denmark, Valby
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
